Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (Au-Assessing Ultegra) multicenter studyCirculation - Steinhubl, SR; Talley, D; Braden, GA; Casterella, PJ; Tcheng, J; Moliterno, DJ
(in Press).